<oohtq class="pcylgnf"></oohtq>

玛雅吧

中

中文 English

About Us
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
News
- Company News
- Media Focus
- With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
- With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
Products
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
R&D
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Services
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate
Contact Us
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.



Zechang (Dabigatran Etexilate Capsules)

Dabigatran Etexilate Capsules

English Name: Dabigatran Etexilate Capsules

Chinese Pinyin: Dabijiaqunzhi Jiaonang

The main ingredient of this product is dabigatran etexilate.

Chemical Name: β-alanine,N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridine-,ethyl ester,methanesulfonate

/en/upload/images/2021/06/17/c1de3cef760f480c8471163cdf016d9b.png

【Name】	Common Name: Dabigatran Etexilate Capsules English Name: Dabigatran Etexilate Capsules Chinese Pinyin: Dabijiaqunzhi Jiaonang
【Ingredients】	Main Ingredient: dabigatran etexilate mesylate Chemical Name: β-alanine,N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridine-,ethyl ester,methanesulfonate Structural Formula: Molecular Formula: C₃₄H₄₁N₇O₅·CH₄O₃S Molecular Weight: 723.86 (methanesulfonate) 627.75 (free matter)
【Description】	This product is a capsule with the content of light yellow granules.
【Indication】	Prevention of stroke and systemic embolism (SEE) in adult patients with nonvalvular atrial fibrillation (NVAF) who have one or more of the following risk factors: · Previous stroke, transient ischemic attack or systemic embolism · Left ventricular ejection fraction < 40% · Symptomatic heart failure, NYHA cardiac function grade ≥ 2 · Age ≥ 75 · Age ≥ 65 years, with any of the following conditions: diabetes, coronary artery disease, or hypertension Treatment of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and prevention of related deaths. Prevention of recurrent deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and related deaths.
【Strength】	(1) 110mg (as dabigatran etexilate), (2) 150mg (as dabigatran etexilate)
【Dosage and Administration】	Orally, swallow whole with water, either with or after a meal. If gastrointestinal symptoms occur, it is recommended to take this product with a meal and/or a proton pump inhibitor, such as pantoprazole. Do not open the capsule. Note: Please refer to the Product Manual for details.